Orphan Drug Designation Denied for ADXS11-001
The U.S. Food and Drug Administration (FDA) has denied the request by Advaxis, Inc. for orphan drug designation (ODD) for their investigative agent ADXS11-001. The request for the ODD included the indication for ADXS11-001 in the treatment of invasive cervical cancer.
The FDA stated that the prevalence of invasive cervical cancer includes all those who have been cured of the disease and thus exceeds the 200,000 person limit necessary for eligibility of ODD.
As phase I study results were promising, Advaxis, Inc may seek Fast Track designation for ADXS11-001 in the near future.
ADXS11-001 includes a Listeria monocytogenes (Lm) bacterium bioengineered to secrete two different antigen-adjuvant fusion proteins targeting cancer cells.
High-Risk Prostate Cancer: Study Highlights Role of Advanced Imaging
Advanced imaging technique called PSMA-PET more sensitive at detecting cancer spread in high-risk hormone-sensitive prostate cancer
Vepdegestrant (ARV-471): FDA Fast Track Designation in ER+/HER2- Metastatic Breast Cancer
Vepdegestrant is an investigational drug belonging to a new class of medications called PROTAC (PROteolysis TArgeting Chimera) protein degraders
